DCC-2812

DCC-2812 is an investigational **oral small molecule** developed as a **selective activator of general control nonderepressible 2 (GCN2), also known as eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4)**. It is currently being studied predominantly in advanced or metastatic **renal cell carcinoma, urothelial carcinoma, and castration-resistant prostate cancer**. The primary objective of clinical trials is to assess the safety, tolerability, and preliminary anti-tumor activity of DCC-2812. Its mechanism involves activating GCN2, which is believed to modulate cellular responses to amino acid deprivation and stress, potentially resulting in antitumor effects in certain cancer types. The drug is in early phase clinical development, with preclinical and phase 1 trials underway[1][3][5][7][9][10].